A U.S. Food and Drug Administration (FDA) advisory committee recently determined that phenylephrine, an ingredient commonly used to treat sinus and nasal congestion, is ineffective in treating these symptoms. This was apparent from research for years, yet large...
News
Latest News
Rubio Habla en La Poderosa
El senador estadounidense Marco Rubio (R-FL) habló con César Grajales de La Poderosa 670 AM en El Panorama Político, sobre la crisis fronteriza, sobre cómo los hispanoamericanos se ven afectados con la realidad del país, sobre los cargos contra el senador Bob Menéndez...
Rubio, Colleagues Reintroduce Bill to Protect Rights of Pregnant Students
Pregnant students are sometimes discriminated against by their schools, either intentionally or unintentionally and there is a concerning lack of awareness about the resources and rights available to them. Due to a lack of services and discrimination, these women may...
Rubio, Colleagues Reintroduce Intelligence Community Workforce Agility Protection Act
Currently, intelligence community civilians are subject to certain tax penalties for job-related relocation requirements, but active-duty military servicemembers are not subjected to the same penalties. These tax benefits, including the ability to deduct moving...
Rubio Delivers Remarks at Senate Intelligence Hearing
Vice Chairman of the Senate Select Committee on Intelligence Marco Rubio (R-FL) delivered opening remarks and questioned witnesses at a hearing on countering China’s influence in the United States. Watch Rubio’s opening remarks here as well as Part I and Part II of...
Rubio-led Resolution to Raise Awareness for Spinal Cord Injuries Passes Senate
Approximately 302,000 Americans live with spinal cord injuries. To help these people achieve a better quality of life, there is a need to increase education and invest in research. U.S. Senators Marco Rubio (R-FL) and Tammy Baldwin (D-WI) successfully led a bipartisan...
Rubio, Bennet Applaud House Passage of RACE for Children Act
Washington, D.C. – U.S. Senators Marco Rubio (R-FL) and Michael Bennet (D-CO), along with Senators Cory Gardner (R-CO) and Chris Van Hollen (D-MD), today applauded the passage in the U.S. House of Representatives of the RACE for Children Act as part of the FDA User Fees reauthorization bill.
In February, Senators Rubio, Bennet, Gardner, and Van Hollen introduced the Research to Accelerate Cures and Equity (RACE) for Children Act to support the development of innovative and promising cancer drugs for children.
“Today’s passage of the RACE for Children Act in the House is great news,” said Rubio. “We are one step closer to developing innovative and promising cancer drugs for children across the country who desperately need them. I urge my colleagues to support this bill when it comes before the Senate. It is crucial this legislation becomes law so that children with cancer have hope for a better future.”
“Today’s passage of the RACE for Children Act in the House is a significant step for children around the country who deserve lifesaving treatments,” said Bennet. “We should be able to tell parents with kids who are battling cancer that we’re doing everything we can to develop breakthrough drugs to treat their children. Today’s House vote brings us closer to that goal. We are thankful to Chairman Lamar Alexander for his leadership in supporting this legislation. And we look forward to the User Fees bill coming before the Senate.”
The bipartisan RACE for Children Act, first introduced in the 114th Congress, would update the Pediatric Research Equity Act (PREA) to reflect the latest advances in cancer drugs. Congress enacted PREA in 2003 to address the scarcity of information about how to treat children with drugs developed and approved for adults. Although PREA has resulted in new information on how to treat children for a multitude of drugs over the years, there are still limited pediatric studies for cancer drugs. This bill would update PREA by ensuring that the most innovative molecular-targeted drugs for cancer are also studied for children when appropriate. The bill also directs the Food and Drug Administration (FDA) to work with manufacturers to speed up studies for drugs that treat other serious or life-threatening diseases in children.
Numerous pediatric oncology groups support the RACE for Children Act, including St. Jude Children’s Research Hospital, St. Baldrick’s Foundation, Live Like Bella Childhood Cancer Foundation, Nemours Children’s Health System, Arnold Palmer Hospital, Moffitt Cancer Center, Kids v. Cancer, the Children’s Hospital Colorado, Children’s Hospital of Philadelphia, Children’s Medical Center of Dallas, Dana-Farber Cancer Institute, Duke University Medical Center, Harvard Medical School, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, NYU Langone Medical Center, Texas Children’s Hospital, the Alliance for Childhood Cancer, the American Society of Clinical Oncology, and the American Cancer Society Cancer Action Network.